HIV/AIDS remains a global epidemic and public health threat. Despite the development of effective antiretroviral drugs, therapy is not curative and is therefore life-long. Long-term therapy is often compromised by viral drug resistance mutations and incomplete adherence. The HIV-1 capsid represents an attractive target for therapy, though currently available inhibitors lack sufficient potency for clinical development. This project will develop a competition-based assay for small molecules targeting a specific pocket in the HIV-1 capsid and will adapt the assay for high-throughput screening of large compound libraries. The assay will be validated by screening a library of 10,000 small molecules and analyzing the hits for antiviral activity and cytotoxicity. This work will facilitate the identification of lead compounds for development of antivirals targeting the HIV-1 capsid, and will identify novel probes for HIV-1 capsid function.
Specific Aims :
Aim 1. Establish a competition-based high-throughput screening assay for small molecules that bind the H3-H4 pocket in HIV-1 CA.
Aim 2. Perform pilot screens to validate the assay.
Aim 3. Test the confirmed hits for antiviral activity against wild type HIV- and mutant viruses that are resistant to known capsid inhibitors.

Public Health Relevance

HIV/AIDS remains a global epidemic and public health threat. Effective therapy requires long- term treatment with antiviral drugs, which is often compromised by viral resistance. This project will develop a competition-based assay for small molecules targeting a specific pocket in the HIV-1 capsid and will adapt the assay for high-throughput screening of large compound libraries, thus facilitating the identification of lead compounds for development of antivirals targeting the HIV-1 capsid.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI114339-02
Application #
8849372
Study Section
AIDS Discovery and Development of Therapeutics Study Section (ADDT)
Program Officer
Sanders, Brigitte E
Project Start
2014-05-15
Project End
2017-04-30
Budget Start
2015-05-01
Budget End
2016-04-30
Support Year
2
Fiscal Year
2015
Total Cost
$353,250
Indirect Cost
$128,250
Name
Vanderbilt University Medical Center
Department
Pathology
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Rankovic, Sanela; Ramalho, Ruben; Aiken, Christopher et al. (2018) PF74 Reinforces the HIV-1 Capsid To Impair Reverse Transcription-Induced Uncoating. J Virol 92:
Carnes, Stephanie K; Sheehan, Jonathan H; Aiken, Christopher (2018) Inhibitors of the HIV-1 capsid, a target of opportunity. Curr Opin HIV AIDS 13:359-365
Saito, Akatsuki; Ferhadian, Damien; Sowd, Gregory A et al. (2016) Roles of Capsid-Interacting Host Factors in Multimodal Inhibition of HIV-1 by PF74. J Virol 90:5808-5823
Halambage, Upul D; Wong, Jason P; Melancon, Bruce J et al. (2015) Microplate-based assay for identifying small molecules that bind a specific intersubunit interface within the assembled HIV-1 capsid. Antimicrob Agents Chemother 59:5190-5